LST News
The FDA has granted orphan drug designation (ODD) to Provectus' small molecule oncolytic immunotherapy PV-10 for the treatment of ocular melanoma. Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
To keep pace with the evolving ecosystem for precision medicine, pharma players must be attuned to three crucial components: data collection, individualized solutions, and supporting business models.
The life sciences industry is taking off, with the medical technology and biotech sectors expected to grow further as traditional pharmaceutical companies are joined by startups and incubator labs driving new research and development. And with life sciences innovation rising, so is demand for the space in which to innovate.
The free one-day meetings are designed to promote interaction among Duchenne families, experts in Duchenne research and drug development, and biotech and pharmaceutical industry partners. They also offer opportunities to connect with each area’s Certified Duchenne Care Center.
Scientists and researchers at the Salk Institute for Biological Studies, which is in California, are currently exploring how biotechnology can help reduce carbon emissions and the effects of global warming.
